|
News FDA Approves Merck’s ISENTRESS (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) recently approved the use of ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicines, for the treatment of HIV-1 infection in pediatric patients two years of age and older and weighing at least 10 kg. |
|
News Merck`s ISENTRESS (raltegravir) Demonstrated Durable Reductions in HIV-1 Viral Load and Sustained Tolerability At Three Years of Treatment in Previously Untreated Adult Patients Infected with HIV-1
Merck announced that new Phase III data showed that adult patients with HIV-1 infection maintained undetectable viral loads and increases in CD4 cell counts at three years of treatment with ISENTRESS® (raltegravir) tablets in combination therapy, comparable to treatment with efavirenz in combination therapy. |
